Abstract

Ovarian cancer has a high mortality and novel-targeted treatment strategies have not resulted in breakthroughs for this disease. Insight into the molecular characteristics of ovarian tumors may improve diagnosis and selection of patients for treatment with targeted therapies. A potential way to achieve this is by means of molecular imaging. Generic tumor processes, such as glucose metabolism (F-18-fluorodeoxyglucose) and DNA synthesis (F-18-fluorodeoxythymidine), can be visualized non-invasively. More specific targets, such as hormone receptors, growth factor receptors, growth factors and targets of immunotherapy, can also be visualized. Molecular imaging can capture data on intra-patient tumor heterogeneity and is of potential value for individualized, target-guided treatment selection. Early changes in molecular characteristics during therapy may serve as early predictors of response. In this review, we describe the current knowledge on molecular imaging in the diagnosis and as an upfront or early predictive biomarker in patients with ovarian cancer.

Original languageEnglish
Pages (from-to)i23-i29
Number of pages7
JournalAnnals of Oncology
Volume27
Issue numberSupplement 1
DOIs
Publication statusPublished - Apr-2016

Keywords

  • ovarian cancer
  • molecular imaging
  • PET
  • RECURRENT EPITHELIAL OVARIAN
  • POSITRON-EMISSION-TOMOGRAPHY
  • ESTROGEN-RECEPTOR EXPRESSION
  • PHASE-III TRIAL
  • F-18-FDG PET/CT
  • GROWTH-FACTOR
  • ANTIANGIOGENIC TREATMENT
  • ZR-89-BEVACIZUMAB PET
  • TUMOR HETEROGENEITY
  • PRIMARY PERITONEAL

Cite this